Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival (RFS) when ...
Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to bolster patient access to community-based oncology trials. | Oncology R&D organization ...
Following a phase 3 knee osteoarthritis failure that its CEO acknowledged caused “great disappointment and concern,” Kolon TissueGene is laying off 37 employees at its Maryland headquarters. | ...
BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca for a rare bone disease market. Alesta is developing a small ...
AstraZeneca has stopped a phase 3 trial of volrustomig in lung | AstraZeneca has stopped a phase 3 trial of volrustomig in ...
Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after ...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...
Antibody platform business OmniAb continues to rack up the Big Pharma partnerships, with Eli Lilly signing off on ...
Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes by more than half in ...
The Massachusetts research site for Merck KGaA’s North American division, EMD Serono, is handing pink slips to 20 staffers, ...
Evaxion has scrapped a next-gen solid tumor vaccine in order to channel resources to a candidate specifically targeting brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results